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Background
Progressive enlargement of the aortic root, leading to dissection, is the main cause 
of premature death in patients with Marfan’s syndrome. Recent data from mouse mod-
els of Marfan’s syndrome suggest that aortic-root enlargement is caused by exces-
sive signaling by transforming growth factor β (TGF-β) that can be mitigated by treat-
ment with TGF-β antagonists, including angiotensin II–receptor blockers (ARBs). We 
evaluated the clinical response to ARBs in pediatric patients with Marfan’s syndrome 
who had severe aortic-root enlargement. 
Methods
We identified 18 pediatric patients with Marfan’s syndrome who had been followed 
during 12 to 47 months of therapy with ARBs after other medical therapy had failed 
to prevent progressive aortic-root enlargement. The ARB was losartan in 17 patients 
and irbesartan in 1 patient. We evaluated the efficacy of ARB therapy by comparing 
the rates of change in aortic-root diameter before and after the initiation of treat-
ment with ARBs. 
Results
The mean (±SD) rate of change in aortic-root diameter decreased significantly from 
3.54±2.87 mm per year during previous medical therapy to 0.46±0.62 mm per year dur-
ing ARB therapy (P<0.001). The deviation of aortic-root enlargement from normal, 
as expressed by the rate of change in z scores, was reduced by a mean difference of 
1.47 z scores per year (95% confidence interval, 0.70 to 2.24; P<0.001) after the ini-
tiation of ARB therapy. The sinotubular junction, which is prone to dilation in 
Marfan’s syndrome as well, also showed a reduced rate of change in diameter dur-
ing ARB therapy (P<0.05), whereas the distal ascending aorta, which does not 
normally become dilated in Marfan’s syndrome, was not affected by ARB therapy. 
Conclusions
In a small cohort study, the use of ARB therapy in patients with Marfan’s syndrome 
significantly slowed the rate of progressive aortic-root dilation. These findings require 
confirmation in a randomized trial.
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Marfan’s syndrome, an autosomal dominant connective-tissue disorder af-fecting approximately 1 in 5000 people, 
is caused by mutations in the gene encoding fibril-
lin-1 (FBN1).1,2 FBN1 mutations lead to defects in 
multiple organ systems, of which the most life-
threatening is progressive enlargement and dissec-
tion of the aortic root.3,4 Current medical manage-
ment of Marfan’s syndrome is focused on serial 
cardiac-imaging studies and the use of pharmaco-
logic agents to reduce hemodynamic stress on the 
aortic wall. Pharmacologic treatment often involves 
the use of beta-adrenergic–receptor antagonists 
(beta-blockers), although other agents, such as an-
giotensin-converting–enzyme (ACE) inhibitors and 
calcium-channel blockers, have been used in pa-
tients who have unacceptable adverse events or no 
response to beta-blockers.5-7
Studies in a mouse model of Marfan’s syn-
drome have shown that a deficiency of fibrillin-1 
in the extracellular matrix leads to excessive signal-
ing by transforming growth factor β (TGF-β), an 
event that probably contributes to the pathogene-
sis of multiple phenotypic features of Marfan’s 
syndrome, including progressive enlargement of 
the aortic root.8-11 These genetically engineered 
mice, in which the pathologic changes in the aor-
tic root closely mimic those seen in humans, were 
subsequently used to demonstrate the therapeutic 
benefit of treatment with TGF-β antagonists in 
vivo. The development of pathologic changes in the 
aortic wall and the progressive dilation of the aor-
tic root were attenuated or prevented by systemic 
treatment with a TGF-β–neutralizing antibody or 
the angiotensin II–receptor blocker (ARB) losartan, 
an antihypertensive medication known to inhibit 
TGF-β signaling.10,12 In comparison, mutant mice 
treated with the beta-blocker propranolol contin-
ued to show substantial aortic-wall pathologic 
changes and had only a moderate reduction in the 
rate of aortic-root dilation. These findings led us to 
hypothesize that treatment with ARBs might be 
effective for the prevention of aortic-root enlarge-
ment and associated cardiovascular pathologic 
changes in patients with Marfan’s syndrome.
Me thods
Study Design and Patients
We retrospectively reviewed the records of all pe-
diatric patients treated in the medical genetics 
clinic of Johns Hopkins Hospital who met the 
Ghent diagnostic criteria13 for Marfan’s syndrome 
and who were followed prospectively from Octo-
ber 1996 through November 2007. The diagnosis 
of Marfan’s syndrome was confirmed in each 
patient after exclusion of other known congeni-
tal aneurysm syndromes on the basis of distin-
guishing phenotypic features, molecular mutation 
analysis, or both (see the Supplementary Appen-
dix, available with the full text of this article at 
www.nejm.org). This retrospective study was ap-
proved by the institutional review board of Johns 
Hopkins University, which waived the requirement 
for informed consent.
We identified a cohort of 18 patients with 
Marfan’s syndrome, 14 months to 16 years of age, 
who had begun ARB therapy between November 
2003 and May 2006 and had continued to receive 
the therapy for at least 1 year of follow-up. An ad-
ditional patient was identified who was prescribed 
an ARB, but this patient was excluded from the 
analysis after we found documented periods of 
nonadherence to therapy. The decision to initiate 
ARB therapy in these patients was made on clini-
cal grounds during routine visits. Although no 
formal inclusion criteria were applied, factors that 
influenced the decision to prescribe ARBs included 
evidence of a rapid rate of change in aortic-root 
diameter despite other medical therapy, including 
beta-blockers with or without ACE inhibitors (11 
patients); an aortic-root diameter of at least 4.0 cm, 
approaching the threshold for surgical interven-
tion (6 patients); and unacceptable adverse events 
associated with conventional pharmacologic agents 
(1 patient). Details of therapy before the initiation 
of ARB treatment are provided in the Supplemen-
tary Appendix.
We identified 65 additional pediatric patients 
with Marfan’s syndrome who had undergone echo-
cardiography at least three times at Johns Hop-
kins Hospital during the study period, had not had 
aortic-root surgery, and had not received ARB 
therapy. All patients in this cohort had received 
beta-blockers according to a dosing regimen simi-
lar to that used in the recipients of ARBs before 
the initiation of ARB therapy.
Therapy with ARBs
Therapy was initiated in 17 patients with the ARB 
losartan (Cozaar, Merck) at an initial oral dose of 
0.6 mg per kilogram of body weight per day; ther-
apy with ACE inhibitors or calcium-channel block-
ers was discontinued at this time. The patients 
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were assessed for adverse events at this starting 
dose over a 3-week period before the dose was 
gradually increased to a sustained dose of 1.4 mg 
per kilogram per day. Therapy was initiated in one 
additional patient with the ARB irbesartan (Avapro, 
Bristol-Myers Squibb) at an initial dose of 1.4 mg 
per kilogram per day and a final dose of 2.0 mg per 
kilogram per day. The blood urea nitrogen and 
creatinine levels (i.e., renal function) and electro-
lyte levels were assessed after the patients had 
received ARB therapy for 3 months. Beta-blocker 
therapy was not decreased or discontinued un-
less the patient had adverse events in association 
with both medications (see the Supplementary Ap-
pendix).
Echocardiography
Two-dimensional transthoracic echocardiograms 
were obtained every 3 to 12 months as part of 
routine clinical care, with the use of transducers 
appropriate for the patient’s size. Complete orthog-
onal sweeps from the subxiphoid, apical, paraster-
nal, and suprasternal-notch windows were obtained 
during each study. Measurements of maximal aor-
tic diameter were taken at the aortic annulus, sino-
tubular junction, ascending thoracic aorta, and aor-
tic root at the sinuses of Valsalva with the use of 
a parasternal long-axis view. The maximal diame-
ter of these segments was determined by measur-
ing from internal edge to internal edge of the aortic 
wall during ventricular systole on an axis perpen-
dicular to the path of blood flow.
All echocardiograms obtained at Johns Hopkins 
Hospital were read by attending cardiologists who 
were not involved in the study and who were un-
aware of the patient’s treatment status. A subgroup 
of studies was performed on selected patients, and 
the results were interpreted at other institutions. 
The majority of the echocardiograms were re-
viewed at Johns Hopkins to ensure standardization 
of measurement practices.
A z score was calculated for each echocardio-
graphic measurement with the use of standard al-
gorithms. The z score represented the standard 
deviation from the mean aortic diameter normal-
ized for the patient’s body-surface area and age.14 
In addition, measurements of heart rate, blood 
pressure, height, and weight were obtained at the 
time of each echocardiogram. Measurements of 
height and weight were used to calculate the body-
mass index and were converted into z scores nor-
malized for sex and age.
Statistical Analysis
The Wilcoxon signed-rank test was used to com-
pare the rates of change in aortic diameter before 
and after the initiation of ARB therapy in individu-
al patients. The one-sample proportion test (sign 
test) was used to test for a consistent decrease in 
the rate of change in aortic-root diameter after 
the initiation of ARB therapy, with a null hypoth-
esis of equal proportions. Linear regression mod-
els were fitted with the use of generalized esti-
mating equations15 with a breakpoint to compare 
the rates of aortic enlargement before and after the 
initiation of ARB therapy, after adjustment for age 
and sex. The last model takes into account the 
correlation between repeated measures within in-
dividual patients. The Mann–Whitney U test was 
used to compare the changes in absolute and 
normalized aortic-root diameter between patients 
treated with ARBs and those treated with beta-
blockers alone. Two-sided P values of less than 0.05 
were considered to indicate statistical significance 
for all statistical tests and models. Stata statistical 
software, version 9.0, was used for all analyses.
R esult s
Characteristics of Patients Receiving  
ARB Therapy
Demographic data, diagnostic criteria, and treat-
ment information for the 18 pediatric patients re-
ceiving ARB therapy are given in Table 1 (and in 
Table 1 in the Supplementary Appendix). All pa-
tients had evidence of severe aortic-root enlarge-
ment, with a mean (±SD) aortic-root diameter of 
3.67±0.53 cm and a mean aortic-root-diameter 
z score of 7.21±2.69 at the time ARB therapy was 
initiated. The median duration of treatment before 
the initiation of ARB therapy was 48.6 months, 
with a median of seven echocardiograms per pa-
tient. The age at initiation of ARB therapy ranged 
from 14 months to 16 years. All patients were re-
ceiving the maximal weight-based dose within 
6 months after the initiation of therapy. The pa-
tients were followed for a median of 26.1 months 
while receiving ARB therapy and had a median of 
five echocardiograms during that period.
At the time of data analysis, two patients, both 
of whom had severe aortic-root enlargement at the 
time of initiation of ARB therapy (4.2 cm in one 
and 4.4 cm in the other), had undergone previ-
ously planned prophylactic aortic-root replacement 
when their aortic-root diameter reached approxi-
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mately 4.5 cm. A third patient required mitral-valve 
repair because of valve insufficiency and left ven-
tricular dysfunction. The data for these three pa-
tients were censored at the time of surgery.
Side Effects
There were no significant changes in mean heart 
rate, mean systolic blood pressure, or mean dia-
stolic blood pressure after the initiation of ARB 
therapy, as compared with the previous period 
when the patients were receiving beta-blockers, 
ACE inhibitors, or calcium-channel blockers (Ta-
ble 2). Laboratory indicators of renal function were 
normal 3 months after the initiation of ARB ther-
apy in all patients: the median blood urea nitro-
gen level was 15 mg per deciliter (5.4 mmol per li-
ter) (range, 7 to 25 mg per deciliter [2.5 to 8.9 mmol 
per liter]), and the median serum creatinine level 
was 0.5 mg per deciliter (44.2 μmol per liter) (range, 
0.3 to 0.8 mg per deciliter [26.5 to 70.7 μmol per 
liter]). No adverse events or side effects were doc-
umented among patients while they were receiving 
ARB therapy.
Body Height and weight during ARB therapy
There was a decline in the rate of change of in-
crease in body height after the initiation of ARB 
therapy, with significant decreases in height ve-
locity and in height-velocity z scores, as compared 
with previous growth rates (see Table 2 in the Sup-
plementary Appendix). No significant changes were 
found in the rate of change in body-weight mea-
surements. This finding might be attributable, at 
least in part, to a reduction in linear growth and 
age-dependent fluctuations in the rate of change 
in body-mass index.
Aortic-Root Dilation During ARB Therapy
The mean rate of change in aortic-root diameter 
in patients before the initiation of ARB therapy was 
3.54±2.87 mm per year. After the initiation of ARB 
therapy, this rate decreased to 0.46±0.62 mm per 
year, which represented a clinically and statistically 
significant difference in aortic dilatation (P<0.001) 
(Table 3). The mean and median rates of increase 
in aortic-root diameter were decreased by factors 
of approximately 8 and 11, respectively (Fig. 1A and 
Table 3). Similarly, the mean rate of change in aor-
tic-root-diameter z scores was 0.97±1.55 per year 
before ARB therapy and decreased to −0.50±0.43 
per year after the initiation of ARB therapy (P<0.001) 
(Table 3 and Fig. 1B). The z score takes into account 
differences in age and body-surface area among 
patients and thus provides a measure that con-
trols for the effects of these variables during fol-
low-up.14
Regression modeling with the use of general-
ized estimating equations, after adjustment for age 
and sex, showed that the initiation of ARB thera-
py was independently associated with an estimated 
Table 1. Characteristics of the 18 Patients Receiving ARB Therapy.*
Variable Value
Age at initiation of ARB — yr
Median 6.5
Range 1–16
Male sex — no. (%) 9 (50)
Race — no. (%)†
White 17 (94)
Black 1 (6)
Aortic-root diameter at initiation of ARB — cm 3.67±0.53
Aortic-root-diameter z score at initiation of ARB 7.21±2.69
Previous treatment — no. (%)
Beta-blocker alone 12 (67)
Beta-blocker plus ACE inhibitor 4 (22)
Beta-blocker plus calcium-channel blocker 2 (11)
Previous treatment dose — mg/kg/day
Beta-blocker 1.83±0.38
ACE inhibitor 0.97±0.27
Calcium-channel blocker 4.12±1.04
No. of echocardiograms per patient
Before initiation of ARB
Median 7
Range 3–15
After initiation of ARB
Median 5
Range 2–10
Duration of treatment — mo
Before initiation of ARB
Median 48.6
Range 12–104
After initiation of ARB
Median 26.1
Range 12–47
* Plus–minus values are means ±SD. ACE denotes angiotensin-converting en-
zyme, and ARB angiotensin II–receptor blocker.
† Race was self-assessed by the patient or parent.
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decrease in the rate of change in aortic-root diam-
eter of 2.75 mm per year (95% confidence inter-
val [CI], 1.65 to 3.84 mm per year; P<0.001) and 
an estimated decrease of 1.27 aortic-root-diameter 
z scores per year (95% CI, 0.57 to 1.97; P<0.001). 
The rate of change in aortic-root diameter was re-
duced among all patients after initiation of ARB 
therapy (P<0.001) (Fig. 2A, and Table 1 in the 
Supplementary Appendix), including the single pa-
tient treated with irbesartan (Fig. 2B).
The sinotubular junction, an aortic segment 
that is also prone to dilation in patients with se-
vere Marfan’s syndrome, also benefited from ARB 
therapy. The mean rate of change in absolute si-
notubular-junction diameter was 2.02±1.13 mm 
per year before the initiation of ARB therapy and 
was reduced to 0.70±1.01 mm per year during ARB 
therapy (P<0.05) (Table 4 and Fig. 1A). The nor-
malized rate of sinotubular-junction enlargement 
decreased from 0.43±0.57 z score per year during 
previous therapy to −0.24±0.44 z score per year 
during ARB therapy (P<0.05) (Table 4 and Fig. 1B). 
In comparison, more distal segments of the as-
cending aorta past the sinotubular junction, which 
are not generally affected by pathologic dilata-
tion in Marfan’s syndrome, showed no change 
in growth measurements after the initiation of 
ARB therapy. Both the mean rate of change in as-
Table 2. Comparison of Hemodynamic Measurements before and after Initiation of ARB Therapy.*
Measurement Before ARB Therapy After Initiation of ARB Therapy P Value†
Median Mean Median Mean
Heart rate (beats/min) 79 81.3±13.0 77 79.0±14.9 0.11
Systolic blood pressure (mm Hg) 98 97.1±9.9 98 97.9±11.0 0.62
Diastolic blood pressure (mm Hg) 59 58.3±6.0 57 57.6±7.1 0.67
* Plus–minus values are means ±SD. All hemodynamic measurements were taken at the time of the echocardiograms. ARB denotes angioten-
sin II–receptor blocker.
† P values for the differences in medians were calculated with the use of the Wilcoxon signed-rank test.
Table 3. Comparison of Annual Rates of Change in Aortic-Root Diameter and z Scores in Patients with Severe Marfan’s Syndrome  
before and after Initiation of ARB Therapy and in Patients with Mild Marfan’s Syndrome Receiving Beta-Blockers Alone.*
Variable
Severe Marfan’s Syndrome 
(N = 18)
Mild Marfan’s Syndrome
(N = 65)
Before ARB Therapy
After Initiation 
of ARB Therapy P Value†
After Initiation of Therapy 
with Beta-Blockers P Value‡
median mean median mean median mean 
Aortic-root-diameter z score
Cohort average§ 6.7 6.52±2.43 NA NA 3.0 3.25±1.52 <0.001
Last measurement¶ 7.2 7.21±2.69 6.3 6.44±2.43 <0.001 NA NA
Change in aortic-root diameter 
Absolute change (mm/yr) 3.3 3.54±2.87 0.3 0.46±0.62 <0.001 1.3 1.71±1.24 <0.001
Normalized change (z scores/yr) 1.0 0.97±1.55 −0.5 −0.50±0.43 <0.001 0.1 0.24±0.50 <0.001
* Plus–minus values are means ±SD. Aortic diameters were measured during echocardiography and converted into rates of enlargement ex-
pressed as millimeters per year. The z scores were calculated from aortic-root diameters normalized for age and body-surface area. ARB de-
notes angiotensin II–receptor blocker, and NA not applicable.
† P values for the comparison of median rates of change in aortic-root diameter before and after the initiation of ARB therapy were calculated 
with the use of the Wilcoxon signed-rank test.
‡ P values for the comparison of median cohort z scores and rates of change in aortic-root diameter between patients with severe and mild 
Marfan’s syndrome were calculated with the use of the Mann–Whitney U test.
§ The mean and median z scores were calculated from all echocardiograms obtained before the initiation of ARB therapy for patients with se-
vere Marfan’s syndrome or from all echocardiograms obtained during childhood for patients with mild Marfan’s syndrome.
¶ The mean and median z scores were calculated from aortic-root diameters measured at the last echocardiogram obtained before the initia-
tion of ARB therapy and at the most recent echocardiogram obtained during ARB therapy.
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cending-aorta diameter and the mean rate of 
change in ascending-aorta-diameter z score were 
essentially unchanged after the initiation of ARB 
therapy (Table 4). Finally, the rates of change in 
absolute aortic-annulus (aortic-valve) diameter and 
aortic-valve-diameter z score were also unaffected 
by the initiation of ARB therapy (Table 4).
Aortic-Root Dilation During Treatment  
with Beta-Blockers Alone
Of the 65 patients with Marfan’s syndrome who 
received beta-blocker therapy alone throughout the 
study period, 36 (55%) were female, 3 (5%) were 
black, and the median age was 12.0 years (range, 
4 months to 19 years). Overall, this population had 
milder aortic-root disease, as evidenced by a re-
duced mean aortic-root-diameter z score for all 
echocardiograms obtained during childhood as 
compared with the mean z score of the cohort 
receiving ARB therapy (3.25±1.52 vs. 6.52±2.43, 
P<0.001). The mean rates of change in aortic-root 
diameter (1.71±1.24 mm per year) and in aortic-
root-diameter z score (0.24±0.50 per year) in pa-
tients receiving beta-blockers alone were signi-
ficantly higher than those in severely affected 
patients receiving ARB therapy (P<0.001 for both 
comparisons) (Table 3).
Discussion
The current study provides early evidence suggest-
ing that the addition of losartan or another ARB 
to the traditional regimen used to treat aortic an-
eurysm in patients with Marfan’s syndrome may 
be beneficial. The initiation of ARB therapy re-
sulted in a significant reduction in the rate of 
change in aortic-root diameter as compared with 
beta-blocker therapy alone. The therapeutic effect 
extended to the sinotubular junction, a site also 
affected by Marfan’s syndrome. In comparison, 
aortic segments not typically affected in Marfan’s 
syndrome (e.g., the ascending aorta above the si-
notubular junction) continued to show an annual 
rate of change in diameter that was appropriate for 
age and body size. Together, these findings sug-
gest that ARBs do not arrest aortic growth but spe-
cifically reduce the pathologic rate of increase in 
the diameter of aortic segments that are already 
of sufficient size to accommodate the physiolog-
ic demands of the tissues for blood flow.
Losartan and irbesartan belong to the ARB 
class of antihypertensive medications that work 
by selectively blocking the angiotensin II type 1 
(AT1) receptor within the renin–angiotensin–aldo-
sterone system.16 In addition to antihypertensive 
and other effects, AT1-receptor blockade induces 
a clinically relevant decrease in TGF-β signal-
ing.12,17,18 This antagonism results in reduced 
plasma levels of free TGF-β, reduced tissue expres-
sion of TGF-β–responsive genes, and reduced lev-
els of intracellular mediators within the TGF-β 
signaling cascade, such as phosphorylated Smad2. 
In a prospective study of renal-transplant recipi-
ents, treatment with normal antihypertensive dos-
es of losartan decreased plasma levels of TGF-β by 
more than 50% within 2 weeks.18 
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Figure 1. Mean Annual Rate of Change in Absolute and Normalized Aortic 
Diameters before and after Initiation of Therapy with an Angiotensin II– 
Receptor Blocker (ARB). 
Panel A shows the rate of change in absolute aortic diameter, and Panel B 
shows the rate of change in aortic-diameter z scores for four aortic seg-
ments that were measured over time in patients with severe Marfan’s syn-
drome. All rates are expressed as means, with error bars representing 
 standard errors. P values were calculated with the use of the Wilcoxon 
signed-rank test.
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The effects of angiotensin II are mediated by 
two receptors, the AT1 receptor and the angioten-
sin II type 2 (AT2) receptor.16 AT1-receptor signal-
ing can increase the production of TGF-β ligands 
and receptors, as well as activators such as throm-
bospondin-1.19 Cellular events observed in the tis-
sues of persons with Marfan’s syndrome, including 
proliferation of vascular smooth-muscle cells, fi-
brosis, and increased expression of matrix metal-
loproteinases 2 and 9, are plausibly attributable to 
increased TGF-β activity.8-10 In contrast, the AT2 
receptor is thought to induce cellular effects op-
posite to those of the AT1 receptor, including an-
tiproliferative and antiinflammatory effects that 
are beneficial in aortic-wall homeostasis.20
Given these mechanisms, the beneficial effects 
of ACE inhibitors and ARBs in this setting might 
be expected to differ. ACE inhibitors limit the pro-
duction of angiotensin II and hence limit signal-
ing through both the detrimental AT1-receptor 
pathway and the potentially protective AT2-recep-
tor pathway and would not influence alternative 
mechanisms for angiotensin II production, such 
as the activity of mast-cell chymase. In contrast, 
ARBs cause selective blockade of the AT1 receptor, 
resulting in overactivation of the AT2-receptor 
pathway.10 In keeping with these mechanistic hy-
potheses, Daugherty and colleagues observed that 
AT1-receptor–blocking agents could prevent ab-
dominal aortic aneurysms induced by the infusion 
of angiotensin II in apolipoprotein E–deficient 
mice, whereas selective AT2-receptor antagonists 
increased both the incidence and the severity of 
abdominal aneurysms in this model.21,22
On balance, however, it seems possible that the 
benefit of AT1-receptor antagonism achieved with 
ACE inhibitors could outweigh the potential nega-
tive influence of AT2-receptor blockade. A small, 
randomized, controlled trial of the ACE inhibitor 
perindopril as compared with placebo in adult 
patients with Marfan’s syndrome who were receiv-
ing beta-blockers showed a reduced rate of change 
in aortic-root diameter that correlated with de-
creased circulating TGF-β levels over a relatively 
short period of follow-up (24 weeks).23 Neverthe-
less, our recent observation of accelerated aortic-
root enlargement in fibrillin-1–deficient mice after 
targeted disruption of the gene encoding the AT2 
receptor further supports our hypothesis that se-
lective AT1-receptor antagonists will provide supe-
rior protection in preventing aneurysmal dilation 
of the aortic root (unpublished data).
There are several limitations of our study. This 
was a nonrandomized, retrospective, observational 
study that evaluated only a small subgroup of pe-
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Figure 2. Change in Aortic-Root Diameter Standardized According to  
the Time of Initiation of Therapy with an Angiotensin II–Receptor  
Blocker (ARB). 
Panel A represents the change over time in aortic-root diameter for each of 
the 18 patients in the analysis, with the solid trend line representing the 
overall mean cha ge in aortic-root diameter before and after the initiation 
of ARB therapy. The time at which ARB therapy was started for all patients 
is standardized at year 0 and is represented by the vertical dashed line. The 
mean rate of change in aortic-root diameter was reduced among all 18 pa-
tients after ARB therapy was initiated (P<0.001, sign test). Panel B repre-
sents the change in aortic-root diameter in the one patient receiving irbe-
sartan. The dashed line at year 0 represents the time of initiation of 
irbesartan and distinguishes the period during which beta-blocker therapy 
alone was administered from the period during which ARB therapy was 
added.
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diatric patients with Marfan’s syndrome who had 
evidence of severe aortic-root enlargement or rapid 
increase in aortic diameter. Selection bias may 
have resulted in the identification of patients who 
were more adherent to, and therefore more likely 
to have a response to, ARB therapy, although it 
could also be hypothesized that patients with es-
tablished severe disease would be less likely to 
have a response to ARB therapy than would pa-
tients with milder disease. Although all patients in 
this study had a reduction in the rate of change 
of aortic-root diameter while receiving ARB ther-
apy, there was variability in this therapeutic re-
sponse (Fig. 2A, and Table 2 in the Supplementary 
Appendix) that may be correlated with the pre-
existing degree of pathologic change or other in-
dividually specific factors, such as genotype. This 
variability may alter the effectiveness of TGF-β 
antagonism, which was not assessed in this study. 
It is also possible that up-regulation of AT1 re-
ceptors in response to chronic receptor antago-
nism may limit the long-term therapeutic effect 
of ARBs.
Despite the encouraging results of this obser-
vational study, equipoise is maintained regarding 
a role for ARB therapy in the treatment of patients 
with Marfan’s syndrome; our findings must be 
confirmed by a prospective, randomized trial. 
A trial coordinated by the Pediatric Heart Network 
of the National Heart, Lung, and Blood Institute, 
comparing losartan with atenolol in patients with 
Marfan’s syndrome, began enrolling patients in 
the winter of 2007, and we encourage all eligible 
patients to enroll in this trial.24,25 Until data from 
this trial are available, evidence for the potential 
efficacy of ARB therapy in this setting should be 
considered preliminary.
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Table 4. Comparison of Annual Rates of Change in Aortic Diameter and z Scores before and after the Initiation of ARB 
Therapy.*
Aortic Segment Before ARB Therapy
After Initiation 
of ARB Therapy P Value†
Median Mean Median Mean
Aortic annulus
Absolute change (mm/yr) 1.0 1.04±1.30 1.1 0.60±0.31 0.53
Normalized change (z scores/yr) 0.2 0.19±0.97 0.1 0.03±1.56 0.18
Sinotubular junction
Absolute change (mm/yr) 1.8 2.02±1.13 0.5 0.70±1.01 <0.05
Normalized change (z scores/yr) 0.3 0.43±0.57 −0.2 −0.24±0.44 <0.05
Ascending aorta
Absolute change (mm/yr) 0.9 1.35±1.07 0.9 1.30±1.06 0.86
Normalized change (z scores/yr) 0.1 0.14±0.39 0.1 0.10±0.38 0.57
* Plus–minus values are means ±SD. Aortic diameters were measured during echocardiography and converted into rates 
of enlargement expressed as millimeters per year. The z scores were calculated from aortic-segment diameters normal-
ized for age and body-surface area and converted into rates expressed as z scores per year. ARB denotes angiotensin 
II–receptor blocker.
† P values for the differences in medians were calculated with the use of the Wilcoxon signed-rank test.
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